Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China
- Written by ACN Newswire

Based on this agreement, Eisai will acquire exclusive...
Read more press releases from ACN Newswire here

Based on this agreement, Eisai will acquire exclusive...